Allogeneic hematopoietic SCT (alloHSCT) is a potential curative treatment in multiple myeloma. However, relapse of multiple myeloma is still a major concern after alloHSCT. 1, 2 Whilst ocular involvement in chronic GVHD (cGVHD) is a frequent complication after alloHSCT, 3 ocular involvement by multiple myeloma is rare. 4 Here, we report a case of a 42-year-old male patient who presented with isolated orbital relapse of multiple myeloma during treatment of severe ocular cGVHD. He received alloHSCT from a gender-and HLA-matched sibling PBSC donor after conditioning with treosulfan and fludarabin as primary treatment for multiple myeloma (IgA-kappa) in partial remission after autologous HSCT in August 2007. Moderate cGVHD (initially overlap syndrome) with quiescent onset (prior steroid-sensitive acute GVHD grade 2) developed 8 months after alloHSCT involving the liver, gastrointestinal tract, oral mucosa and diffuse involvement of the fascia (predominately involving the trunk) that progressed 2 months later to moderate oral, severe cutaneous and severe bilateral ocular cGVHD with dry eye, pseudoptosis, blepharitis, persistent inflammatory activity of the conjunctiva and recurrent corneal erosions. Visual acuity was decreased due to corneal thinning and scarring after bilateral corneal ulceration. Ocular GVHD was treated topically with CYA 0.05% and steroid eye drops, unpreserved artificial tears and gels in addition to various systemic immunosuppressive medications including mycophenolate mofetil, steroids, tacrolimus and extracorporeal photopheresis. During immunosuppressive treatment the patient was stable for several months, but developed a painless subconjunctival redness and discrete swelling in the right eye 51 months after alloHSCT ( Figure 1a ). The patient subsequently developed painless exophthalmos, periorbital and conjunctival swelling, reduced ocular motility, chemosis, punctate keratopathy and corneal erosion of the right eye. Magnetic resonance imaging (MRI) revealed an isolated orbital tumor surrounding the globe, which exhibited the criteria of a plasma cell tumor. Subconjunctival biopsy revealed infiltration by plasma cells of the same isotype clone as the original multiple myeloma. Further staging examinations (whole-body positron emission tomography-computed tomography (PET/CT)/light chain assay, BM aspiration and immunofixation of serum and urine) were performed that excluded additional manifestations. Exophthalmos and swelling resolved after systemic steroid treatment and orbital radiotherapy (cumulative dose of 26 Gy in 2-Gy fractions). Amniotic membrane transplantation was performed for persistent corneal erosion and ulceration. Owing to progression of cutaneous deep sclerosis after reduction of immunosuppression, rituximab was applied resulting in significant improvement of cGVHD. However, 1 year later, the patient presented again with painless swelling of the upper lid and exophthalmos of the right eye (Figure 1b) . MRI scan showed again an orbital tumor mass ( Figure 1c) ; however, PET/CT scan was negative. Orbital biopsy confirmed an infiltration of the same plasma cell clone (Figure 2 ). After repeated orbital radiotherapy (additional cumulative dose 36 Gy in 2-Gy fractions), combined with systemic chemotherapy with CY, bortezomib and dexamethasone exophthalmos and swelling resolved completely. During the following 9 months no further recurrence of multiple myeloma was diagnosed and cutaneous cGVHD showed further improvement while oral and ocular cGVHD remained stable.
Ophthalmic manifestations (ocular, orbital or neuro-ophthalmic) of multiple myeloma are rare and variable. They can be the result of direct tissue infiltration by plasma cells or from increased blood viscosity. 4 Orbital involvement as an indicator of extramedullary recurrence of multiple myeloma in patients thought to be in remission is an exceptional case. 5 Common symptoms of orbital involvement by multiple myeloma are proptosis, decreased vision, diplopia, swelling and ptosis. Our patient presented with a subconjunctival swelling in the right eye as unspecific early finding followed by the above-mentioned typical symptoms of an orbital lesion later with histopathology confirming diagnosis.
Although cGVHD is associated with a graft-versus-myeloma effect preventing relapse after alloHSCT, 6 relapses with extramedullary manifestations appear to occur more frequently due to altered biology and local immunological escape effects. 7, 8 Furthermore, malignant plasma cells may have survived in the fatty tissue of the orbit, potentially providing a sanctuary for persistence of malignant cells. Our observation adds an alternative, not yet described aspect: as the isolated extramedullary relapse included a subconjunctival infiltrate and occurred at a site exposed to intense topical immunosuppressive treatment including CYA in addition to a multiagent systemic immunosuppression despite active cGVHD, the topical immunosuppression might have been a contributing factor for orbital relapse of multiple myeloma in the present case. 
